Maintained Efficacy of the Tyrosine Kinase Inhibitor Imatinib Mesylate in a Patient With Rheumatoid Arthritis

被引：17

作者：

Eklund, Kari K. ^{[1
]}

Lindstedt, Ken ^{[2
]}

Sandler, Charlotta ^{[1
]}

Kovanen, Petri T. ^{[2
]}

Laasonen, Leena ^{[3
]}

Juurikivi, Annika ^{[1
]}

Wolff, Henrik ^{[4
]}

Mykkaenen, Marko ^{[5
]}

Joensuu, Heikki ^{[6
]}

机构：

[1] Univ Helsinki, Cent Hosp, Div Rheumatol, Dept Med, SF-00130 Helsinki, Finland

[2] Wihuri Res Inst, SF-00140 Helsinki, Finland

[3] Univ Helsinki, Cent Hosp, Dept Radiol, SF-00130 Helsinki, Finland

[4] Univ Helsinki, Cent Hosp, Dept Pathol, SF-00130 Helsinki, Finland

[5] Univ Helsinki, Cent Hosp, Dept Surg, SF-00130 Helsinki, Finland

[6] Univ Helsinki, Cent Hosp, Dept Oncol, SF-00130 Helsinki, Finland

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2008年 / 14卷 / 05期

关键词：

rheumatoid arthritis; treatment; tyrosine kinases;

D O I：

10.1097/RHU.0b013e318188b1ce

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Imatinib mesylate (Gleevec) is a selective tyrosine kinase inhibitor used for treatment of malignant diseases, chronic myeloid leukemia, and gastrointestinal stromal tumor (GIST), in particular.(1) Imatinib inhibits the stem cell factor receptor (KIT), which in synovial tissue is expressed mainly by the mast cells,(2) the platelet-derived growth factor (PDGF) receptor expressed by synoviocytes,(3) and the macrophage colony-stimulating factor receptor (c-fms),(4) which are all implicated in the pathogenesis of rheumatoid arthritis (RA). We and others have recently reported that imatinib possesses antirheumatic activity.(5-7) Of 3 patients we reported in a 12 week-study,(5) 2 patients withdrew at 2 and 4 months because of adverse events. We describe 1 patient with severe treatment refractory RA who continued treatment and showed a marked and long-lasting clinical improvement during 24 months of imatinib treatment.

引用

页码：294 / 296

页数：3

共 13 条

[1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[2]

Ceponis A, 1998, J RHEUMATOL, V25, P2304

[3] Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib [J].

Dewar, AL ;

Cambarerí, AC ;

Zannettino, ACW ;

Miller, BL ;

Doherty, KV ;

Hughes, TP ;

Lyons, AB .

BLOOD, 2005, 105 (08) :3127-3132

[4] Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients [J].

Eklund, K. K. ;

Remitz, A. ;

Kautiainen, H. ;

Reitamo, S. ;

Leirisalo-Repo, M. .

RHEUMATOLOGY, 2006, 45 (12) :1573-1575

[5] Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases [J].

Eklund, KK ;

Joensuu, H .

ANNALS OF MEDICINE, 2003, 35 (05) :362-367

[6] Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia:: a potential approach to the treatment of arthritis [J].

Juurikivi, A ;

Sandler, C ;

Lindstedt, KA ;

Kovanen, PT ;

Juutilainen, T ;

Leskinen, MJ ;

Mäki, T ;

Eklund, KK .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1126-1131

[7] Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia [J].

Kindler, T ;

Breitenbuecher, F ;

Marx, A ;

Beck, J ;

Hess, G ;

Weinkauf, B ;

Duyster, J ;

Peschel, C ;

Kirkpatrick, CJ ;

Theobald, M ;

Gschaidmeier, H ;

Huber, C ;

Fischer, T .

BLOOD, 2004, 103 (10) :3644-3654

[8] RADIOGRAPHIC EVALUATION OF RHEUMATOID-ARTHRITIS AND RELATED CONDITIONS BY STANDARD REFERENCE FILMS [J].

LARSEN, A ;

DALE, K ;

EEK, M .

ACTA RADIOLOGICA-DIAGNOSIS, 1977, 18 (04) :481-491

[9] Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia [J].

Miyachi, K ;

Ihara, A ;

Hankins, RW ;

Murai, R ;

Maehiro, S ;

Miyashita, H .

CLINICAL RHEUMATOLOGY, 2003, 22 (4-5) :329-332

[10] Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis [J].

Paniagua, Ricardo T. ;

Sharpe, Orr ;

Ho, Peggy P. ;

Chan, Steven M. ;

Chang, Anna ;

Higgins, John P. ;

Tomooka, Beren H. ;

Thomas, Fiona M. ;

Song, Jason J. ;

Goodman, Stuart B. ;

Lee, David M. ;

Genovese, Mark C. ;

Utz, Paul J. ;

Steinman, Lawrence ;

Robinson, William H. .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2633-2642

← 1 2 →